Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
An announcement from IQ-AI ( (GB:IBAI) ) is now available.
Imaging Biometrics Limited reported a half-year revenue of £394,002, a decrease of 11% compared to the previous year, primarily due to a one-off grant and exchange rate differences. Despite this, the company reduced its loss significantly to £89,652 from £274,309, with net assets increasing to £513,624. The company is advancing its IB003 gallium maltolate (GaM) program, having completed Phase 1 trials and preparing for Phase 2, while also addressing challenges in expanding access to treatment. Additionally, the company is focusing on direct engagement for its IB Clinic product and enhancing its IB Nimble platform to improve clinical impact and commercialization prospects.
More about IQ-AI
Imaging Biometrics Limited operates in the medical imaging industry, focusing on advanced imaging technologies and solutions. The company offers products like IB Clinic and IB ASL, which are designed to enhance neuro-oncology imaging and cerebral perfusion evaluation. Their market focus includes clinicians, decision-makers in oncology, neurosurgery, radiology, and patient advocacy communities.
Average Trading Volume: 398,843
Technical Sentiment Signal: Strong Sell
Current Market Cap: £1.6M
For an in-depth examination of IBAI stock, go to TipRanks’ Overview page.